Program
isatuximab
Also written as “Isatuximab SAR650984”, “Isatuximab” and “isatuximab SAR650984”.
Its studies are mostly in Multiple Myeloma · Lymphoma · Immune System Diseases · Precursor Cell Lymphoblastic Leukemia-Lymphoma · Anemia, Hemolytic, Autoimmune, led by 3 companies.
Drug pageIsatuximab: every studyAll 73 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Sanofiits history only | 215 open or running | phase 3since Dec 4, 2016 | Mar 9, 2010 | Apr 5, 2027phase 3 · NCT03319667 |
| GlaxoSmithKline | 11 open or running | phase 2since Oct 13, 2025 | Oct 13, 2025 | none ahead |
| Hoffmann-La Rocheits history only | 10 open or running | phase 2since May 31, 2018 | May 31, 2018 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of GlaxoSmithKline only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Oct 13, 2025First study: phase 2 study in Multiple MyelomaFirst studyNCT07217184 · 30 enrolled · United States, Australia, Brazil and more
TargetBeta
“A humanized IgG1 monoclonal antibody directed against the cell surface glycoprotein CD-38 ”NCIt, by rule
“Lymphocyte differentiation antigen CD38 inhibitor”ChEMBL 37, by rule
Other programs on CD38
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| daratumumabrule | Johnson & Johnson | phase 4 | 44 |
| felzartamabrule | Biogen | phase 3 | 15 |
| mezagitamabrule | Takeda | phase 3 | 11 |
| lumrotatugrule | Keymed Biosciences | phase 3 | 10 |
| Anti-CD38 Monoclonal Antibody SCTC21Crule | Sinocelltech Group | phase 3 | 5 |
| sanritatugrule | Hangzhou Sumgen Biotech | phase 3 | 5 |
| CID-103rule | CASI Pharmaceuticals | phase 2 | 3 |
| Anti-BCMA/CD38/CD3 Trispecific Antibody ABBV-2001 | AbbVie | phase 2 | 2 |
| Anti-CD38 Monoclonal Antibodyrule | Chongqing Genrix Biopharmaceutical | phase 2 | 1 |
| Anti-CD38 Antibody-drug Conjugate ABBV-438 | AbbVie | phase 1 | 1 |
Studies
The one study GlaxoSmithKline leads. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07217184Multiple Myeloma · United States, Australia, Brazil and more | 2 | Active, not recruiting | Apr 17, 2025 | 30 |
How it is read
Names in the registry
- “Isatuximab SAR650984”, 11 entries
- “Isatuximab”, 6 entries
- “isatuximab SAR650984”, 3 entries
- “Isatuximab intravenous (IV)”, 1 entry
- “Isatuximab subcutaneous (SC)”, 1 entry
Codes read as this program: SAR650984.
Conditions, from the studies’ own filings
- Multiple Myeloma, 14 studies
- Lymphoma, 1 study
- Immune System Diseases, 1 study
- Precursor Cell Lymphoblastic Leukemia-Lymphoma, 1 study
- Anemia, Hemolytic, Autoimmune, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.